Trial · NCT01031836
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Area Undre Curve (AUC) of MEDI-545 After First Dose in Stage I | MEDI-545 1.0 mg/kg IV | 261.98 | Full Range 16.8 | day*ug/mL | |
| Area Undre Curve (AUC) of MEDI-545 After First Dose in Stage I | MEID-545 3.0 mg/kg IV | 647.93 | Full Range 7.4 | day*ug/mL | |
| Area Undre Curve (AUC) of MEDI-545 After First Dose in Stage I | MEDI-545 10.0 mg/kg IV | 3040.83 | Full Range 24.2 | day*ug/mL | |
| Area Undre Curve (AUC) of MEDI-545 After First Dose in Stage I | MEDI-545 100mg SC | 239.16 | Full Range 239.16 to 239.16 | day*ug/mL | |
| Area Undre Curve (AUC) of MEDI-545 After First Dose in Stage I | MEDI-545 600mg IV | 2308.44 | Full Range 2308.44 to 2308.44 | day*ug/mL | |
| Area Undre Curve (AUC) of MEDI-545 After First Dose in Stage I | MEDI-545 1200mg IV | 5235.41 | Full Range 11.6 | day*ug/mL | |
| AUC0-14 of MEDI-545 After First Dose in Stage I | MEDI-545 1.0 mg/kg IV | 151.28 | Geometric Coefficient of Variation 19.3 | day*ug/mL | |
| AUC0-14 of MEDI-545 After First Dose in Stage I | MEID-545 3.0 mg/kg IV | 432.26 | Geometric Coefficient of Variation 11.0 | day*ug/mL | |
| AUC0-14 of MEDI-545 After First Dose in Stage I | MEDI-545 10.0 mg/kg IV | 1728.01 | Geometric Coefficient of Variation 16.8 | day*ug/mL | |
| AUC0-14 of MEDI-545 After First Dose in Stage I | MEDI-545 100mg SC | 128.06 | Geometric Coefficient of Variation 56.1 | day*ug/mL | |
| AUC0-14 of MEDI-545 After First Dose in Stage I | MEDI-545 600mg IV | 1965.44 | Geometric Coefficient of Variation 41.4 | day*ug/mL | |
| AUC0-14 of MEDI-545 After First Dose in Stage I | MEDI-545 1200mg IV | 4583.55 | Geometric Coefficient of Variation 15.2 | day*ug/mL | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEDI-545 1.0 mg/kg IV | Any AE | 5 | Participants | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEID-545 3.0 mg/kg IV | Any AE | 4 | Participants | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEDI-545 10.0 mg/kg IV | Any AE | 5 | Participants | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEDI-545 100mg SC | Any AE | 5 | Participants | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEDI-545 600mg IV | Any AE | 5 | Participants | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEDI-545 1200mg IV | Any AE | 5 | Participants | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEDI-545 1.0 mg/kg IV | Any AE of CTC grade at least 3 | 0 | Participants | |
| Number of Participants With Each Category of Adverse Events in Stage I | MEID-545 3.0 mg/kg IV | Any AE of CTC grade at least 3 | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01031836/results